ID
26392
Beskrivning
Study Part: Breakfast Details Week 1 PK Visit (Visit 3). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165
Nyckelord
Versioner (1)
- 2017-10-16 2017-10-16 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
16 oktober 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Breakfast Details Week 1 PK Visit (Visit 3) Ropinirole Parkinson Disease 101468/165
Breakfast Details Week 1 PK Visit (Visit 3)
- StudyEvent: ODM
Similar models
Breakfast Details Week 1 PK Visit (Visit 3)
- StudyEvent: ODM
C0019994 (UMLS CUI [1,2])
C1301880 (UMLS CUI [1,2])
C2698559 (UMLS CUI [1,3])
C0444930 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,2])